List of Small Molecule Pharmaceuticals Companies in Illinois - 40

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

AKAVA Therapeutics is developing first-in-class small molecule therapeutics that inhibit protein aggregation, inhibit enzymes and inhibit cancer for a variety of neurodegenerative diseases.

AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on identifying, acquiring, developing and commercializing therapies for the unmet medical needs of critical care patients and those with severe, often rare, disorders for which few effective treatments are available.

Through our drug development expertise in brain & CNS disorders, we have developed a unique medicinal chemistry platform to discover novel product candidates. The compounds we have discovered work through modulation of NMDA receptors to avoid caustic effects associated with over-activation or full inhibition.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company’s pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Biocatalysts is a biotechnology company producing speciality enzymes at commercial scales for a variety of industries. Biocatalysts has used its wide range of technical, commercial and regulatory capabilities to develop #BiobasedValue for our customers. Established in 1983, Biocatalysts has been a member of the international BRAIN Group since 2018. Next to first-class research and development services for industry customers to create bio-based products and processes, the Group distributes specialty ingredients, like enzymes or bioactive natural products. Own fermentation and production facilities in Continental Europe, UK and the US, together with the associated biotechnological solution competency complete the value chain within the BRAIN Group.

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

Since 2005, the Chicago Research Center's dedicated team of qualified, board certified physicians, licensed clinicians, psychometricians and trained support staff have taken part in more than 750 clinical trials over the past 12 years. As an independent research center, CRC specializes in the pharmaceutical and biotechnology industries, focusing their studies in areas including psychiatric, sleep, and general medicine. Located in Portage Park, but serving all of Chicagoland, CRC takes the utmost care to ensure participants of their clinical trials have a safe and rewarding experience. The results of their efforts continue to exceed sponsor expectations for reliability, dependability, human protection, and overall performance. With a combined 25 years of expertise in the industry, Chicago Research Center continues to impact lives through novel developments and provides leadership and continuity to the research industry.

CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP).

Clinical Investigation Specialists, Inc. (CIS), is an independent, premier Clinical Research Management Organization. CIS has conducted Phases I-IV clinical trials for pharmaceutical and biotechnology companies. CIS is committed to providing personalized attention and services by utilizing resources other companies cannot provide. We maintain a proactive pursuit of value added services to meet our clients' changing needs. Our extensive CIS/MD Network consists of the most qualified Board Certified physicians covering all major therapeutic areas. We are proud to break the mold by distinguishing ourselves as a clinical research management organization that is on the cutting edge of medicine. CIS offers not only services you may receive from a CRO & SMO, but also services encompassed by a hands on Research Management Organization. Sounds like a smart choice for companies looking for an efficient means to move their products through the pipeline with more personalized attention. There are many advantages when you choose CIS for your upcoming trials. Our experienced Investigators and Research Coordinators offer innovative ideas every step of the way to help you achieve your desired results.

Cosmos Health Inc. is a global healthcare group that was incorporated in 2009 in Chicago, Illinois. Cosmos Health Inc. is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia, and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Elorac, Inc. is a specialty pharmaceutical company devoted to developing, commercializing, and marketing dermatology products. Elorac has over 20 novel prescription products in development. Our products embody proprietary technologies or compounds, all protected by patents or covered by proprietary technology.

Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Eton Pharmaceuticals, Inc. is a Deer Park, Illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway. Our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.

Founded in 2017, Meitheal Pharmaceuticals is a privately owned pharmaceutical company focusing on generic injectable products. Headquartered near Chicago, Illinois, Meitheal has an established management team and an aggressive growth strategy. Through global partnerships, our goal is to bring supply to US healthcare providers that demand a reliable, high quality, yet affordable supply of injectables.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.

At Nosco, we specialize in creating high-quality printed packaging solutions for the pharmaceutical, home healthcare + OTC, natural health and consumer products markets. With a focus on reliability, quality and responsiveness, we deliver cartons, labels, literature and flexible packaging tailored to each customer's unique needs. Our Brand Promise at Work Through our work together, we provide printed packaging that helps our customers save lives, promote health and encourage happiness. We do this every day with reliability, quality and responsiveness.

Orochem Technologies Inc. has manufactured sample preparation products, chromatography columns, proteomics and oligo research products, and positive pressure processors in the USA since 1996. Orochem offers final products, contract synthesis of resins and oligo, and contract packing services. Orochem provides Simulated Moving Bed (SMB) Chromatography technology for the laboratory scale, pilot scale, and large-scale purification of commercially viable molecules for its customers worldwide. Orochem's products and services for Simulated Moving Bed Chromatography include the synthesis and manufacture of stationary phases "tailored for specific separations", a uniquely engineered SMB system, and the installation and commissioning of the SMB systems at customer sites with well-trained Orochem technical service engineers. Orochem owns several manufacturing facilities around the world. The Naperville, Illinois, USA site has about 84,000 square feet of manufacturing area where most of the Membrane Filter Plates, Silica manufacturing, Silica bonding, Solid Phase Extraction products, and HPLC Columns are manufactured. Orochem India, Mumbai has a 20,000-square-foot facility and manufactures Sample prep products for Discovery and clinical research organizations in Asia. Simulated Moving Bed chromatography systems are designed, built, and assembled completely at our US locations in Naperville Illinois.

Orthogonal is a product development and consulting firm that creates software for medical hardware such as smartphone apps talking to devices that operate directly on the human body to treat sickness and injury. Our solutions take on some of the toughest healthcare problems facing our loved ones, healthcare system, and society. Working at Orthogonal, you will immediately be exposed to projects designed to: •Revolutionize the rapid detection of COVID-19 and other infectious diseases. •Improve the minute-by-minute lives of millions of people suffering from the lifetime affliction of diabetes by managing the delivery of insulin. •Transform the early diagnosis of Alzheimer's disease. •Give patients an at-home means to stimulate specific nerves to treat chronic conditions that drag down their quality of everyday life. •Power the next generation of omics-based cancer-detection systems. Specifically, Orthogonal develops Software as a Medical Device (SaMD), digital therapeutics (DTx), and other types of connected medical devices. We accelerate the product innovation pipeline at medical device, diagnostics, and pharmaceutical manufacturers to modernize patient care and gain competitive advantage. Orthogonal's industry-leading experience with SaMD enables us to rapidly develop, launch, and continuously improve connected, compliant products – and we offer this innovative approach to clients, so they can build their own SaMD product development workflows. Over the last decade, we've worked with partners ranging from startups to Fortune 500 firms to develop and bring their connected devices to market in a highly regulated space.

OWP Pharmaceuticals provides FDA approved epilepsy medications to patients at affordable prices in the United States. We have created a business model that has a significant tie to a "Not for Profit" organization named the ROW Foundation. Through this model both organizations have a vision to drastically improve the lives of epilepsy patients throughout the world including under-resourced patients outside of the United States through increase education, diagnosis and treatment.

Pagari Life Science Corp is a biotechnology company dedicated to the development and commercialization of a new generation of safe anti-herpetic viral drugs and advanced healing drugs. The company is revolutionizing cold sore treatment with the commercial launch of Helocaine®.

The future of mental wellness is being built today. Through its diversified investment fund, Palo Santo is positioned to increase the supply of clinically effective, affordable, and accessible mental health and addiction treatment solutions needed in today's world. Supported by a rapidly growing body of evidence and strong FDA support, psychedelic-assisted treatments represent a paradigm shift in mental health care. Yet the emerging ecosystem of business opportunities is highly fragmented and, with a lack of institutional capital available, Palo Santo is targeting high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams. These businesses are positioned to have a profound impact on treating conditions such as depression, PTSD, anxiety, OCD, drug and alcohol dependence, chronic pain, Alzheimer's, and a range of inflammatory-related illnesses.

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.

Generics

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India. Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement — elements that are key to our success.

Protide Pharmaceuticals, Inc. is a fully integrated organization devoted to discovery, development and the advancement of technologies and processes in clinical cell therapy, regenerative medicine, transplantation and cell engineering. With over 35 years of innovative products and services, and hundreds of clinical trials using our technology, we positively impact science through knowledge. Inspired by the scientists, patients, and physicians we support, Protide continues as an entrepreneurial, science driven organization.

Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support your discovery, lead molecule development and drug commercialization – from process development and analytical development, to stability services and cGMP API manufacturing. Our facilities are routinely inspected by the FDA and other global regulatory authorities. With our extensive organic chemistry & separations expertise, Regis also manufactures an innovative line of proprietary chromatography products sold throughout the world. Regis is privately owned and operated and has been in business in the Chicagoland area since 1956.

Sunny Biotechnology Co focuses on the development of polyclonal, monoclonal, secondary antibodies, serum-free media and supplements for stem cell research, peptide synthesis service, and related biotech products for life science research and clinical diagnosis.

Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).

VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.

Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.

ZS is the place where ambitions are welcomed and where passion changes lives. As a management consulting and technology firm focused on transforming healthcare and beyond, we invite you to grow with our global team of bright minds. At ZS, we believe that making an impact demands a different approach; and that's why here your ideas elevate actions, and here you'll have the freedom to define your own path and pursue cutting-edge work. Join us and work side-by-side with like-minded people who rise in care of humanity's greatest challenges to define what's next. To learn more, visit https://www.zs.com/

zuChem is a leading producer of unique sugars for human health and nutrition. zuChem develops proprietary technologies for the manufacture of glycochemicals and carbohydrates for use in the food, specialty and fine chemical markets. The zuChem approach is unique, combining new proprietary technologies with the more traditional synthetic techniques. zuChem researchers have a proven track record in developing and implementing scalable, industrial quality processes.